Lamotrigine Tablet, Extended Release
Product Images NDC 70518-1153

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 70518-1153). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Lamotrigine 50mg 70518 1153 01

This text provides information about Lamotrigine tablets manufactured by Torrent Pharma Inc. The medication is an extended-release type with a strength of 50 mg. The usual dosage instructions can be found in the insert. It is advised to keep the medication out of the reach of children and store it between 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F). The quantity is 50 tablets per box. The tablets are round and green in color. The packaging information indicates it was repackaged by RemedyRepack Inc. in Indiana, PA.*

FDA Label Image

Remedy_label (Remedy Label)

This text provides information about Lamotrigine tablets manufactured by Torrent Pharma Inc. The medication is in extended-release form and the usual dosage instructions can be found in the insert. The tablet is green in color and has a strength of 50 mg. It is important to keep this medication out of reach of children and store it at temperatures between 20-25°C (68-77°F). The NDC number for this tablet is 13668-0340-30. Additionally, the medication may be repackaged by RemedyRepack Inc. located in Indiana, PA. For more details on usage and storage, refer to the provided information.*

FDA Label Image

Image Clinicalstudy1 Partialonsetseizure

This appears to be a comparison chart showing responder rate percentages for improvement, worsening, and placebo effects for two different groups: one group taking Lamotrigine Extended-Release Tablets and the other group taking a placebo. The responder rate for the Lamotrigine group is 75% for equal or greater improvement and -100% for worsening. The chart seems to indicate treatment outcomes and their percentages in relation to the two groups.*

FDA Label Image

Image Clinicalstudy2 Partialonsetseizure

FDA Label Image

Structure

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.